Oxidative stress and cerebral endothelial cells: Regulation of the blood-brain-barrier and antioxidant based interventions

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 822-829

  Freeman, Linnea R ^a   Keller, Jeffrey N ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Antioxidant; Blood brain barrier; Cerebral endothelial cell; Neurodegeneration; Oxidative stress; Vascularization

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAROTENOID; FLAVONOID; LEVODOPA; NITECAPONE; NORPHENAZONE; POLYPHENOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOL; SELEGILINE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN ISCHEMIA; CYTOARCHITECTURE; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HIV ASSOCIATED DEMENTIA; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TRAUMATIC BRAIN INJURY;

ANTIOXIDANTS; BLOOD-BRAIN BARRIER; BRAIN; ENDOTHELIUM, VASCULAR; HUMANS; OXIDATIVE STRESS;

EID: 84858153711     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.12.009     Document Type: Review

References (136)

1. Shulman R.G., Rothman D.L., Behar K.L., Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 2004, 27:489-495.
2. Lochhead J.J., McCaffrey G., Quigley C.E., Finch J., DeMarco K.M., Nametz N., Davis T.P. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J. Cereb. Blood Flow Metab. 2010, 30:1625-1636.
3. Grammas P., Martinez J., Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med. 2011, 13:e19.
4. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001, 18:685-716.
5. Halliwell B. Antioxidants and human disease: a general introduction. Nutr. Rev. 1997, 55:S44-S49. (discussion S49-52).
6. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic. Res. 1999, 31:261-272.
7. Mariani E., Polidori M.C., Cherubini A., Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 827:65-75.
8. Halliwell B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition, Mutat Res 1999, 443:37-52.
9. Tayarani I., Chaudiere J., Lefauconnier J.M., Bourre J.M. Enzymatic protection against peroxidative damage in isolated brain capillaries. J. Neurochem. 1987, 48:1399-1402.
10. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
11. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 1996, 149:21-28.
12. Zhu X., Lee H.G., Casadesus G., Avila J., Drew K., Perry G., Smith M.A. Oxidative imbalance in Alzheimer's disease. Mol. Neurobiol. 2005, 31:205-217.
13. Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1998, 1366:225-233.
14. Sheng B., Wang X., Su B., Lee H.G., Casadesus G., Perry G., Zhu X. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's Disease. J. Neurochem. 2012, 120:419-429.
15. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20(Suppl 2):S265-S279.
16. Swerdlow R.H. The neurodegenerative mitochondriopathies. J. Alzheimers Dis. 2009, 17:737-751.
17. Chandrasekaran K., Giordano T., Brady D.R., Stoll J., Martin L.J., Rapoport S.I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res. Mol. Brain Res. 1994, 24:336-340.
18. Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21:455-462.
19. Nagy Z., Esiri M.M., LeGris M., Matthews P.M. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol. 1999, 97:346-354.
20. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
21. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
22. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
23. Van Muiswinkel F.L., Veerhuis R., Eikelenboom P. Amyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. J. Neurochem. 1996, 66:2468-2476.
24. Klegeris A., McGeer P.L. beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J. Neurosci. Res. 1997, 49:229-235.
25. Favit A., Grimaldi M., Alkon D.L. Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway. J. Neurochem. 2000, 75:1258-1263.
26. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000, 75:436-439.
27. Keller J.N., Hanni K.B., Markesbery W.R. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech. Ageing Dev. 2000, 113:61-70.
28. Gregori L., Hainfeld J.F., Simon M.N., Goldgaber D. Binding of amyloid beta protein to the 20 S proteasome. J. Biol. Chem. 1997, 272:58-62.
29. Dorheim M.A., Tracey W.R., Pollock J.S., Grammas P. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1994, 205:659-665.
30. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
31. Parker W.D., Parks J.K., Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 2008, 1189:215-218.
32. Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 2009, 218:235-246.
33. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 2006, 26:5256-5264.
34. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
35. Chinta S.J., Andersen J.K. Redox imbalance in Parkinson's disease. Biochim. Biophys. Acta 2008, 1780:1362-1367.
36. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
37. Kopin I.J. MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. Environ. Health Perspect. 1987, 75:45-51.
38. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
39. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
40. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277:1641-1644.
41. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10:119-127.
42. Kuroda Y., Mitsui T., Akaike M., Azuma H., Matsumoto T. Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism. J. Neurol. Neurosurg. Psychiatry 2001, 71:231-234.
43. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
44. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
45. Kuroda Y., Mitsui T., Kunishige M., Matsumoto T. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem. Biophys. Res. Commun. 2006, 348:787-793.
46. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
47. Lassmann H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J. Neural Transm. 2011, 118:747-752.
48. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
49. Lassmann H. Pathophysiology of inflammation and tissue injury in multiple sclerosis: what are the targets for therapy. J. Neurol. Sci. 2011, 306:167-169.
50. Mahad D., Lassmann H., Turnbull D. Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol. Appl. Neurobiol. 2008, 34:577-589.
51. Veto S., Acs P., Bauer J., Lassmann H., Berente Z., Setalo G., Borgulya G., Sumegi B., Komoly S., Gallyas F., Illes Z. Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain 2010, 133:822-834.
52. van Horssen J., Schreibelt G., Drexhage J., Hazes T., Dijkstra C.D., van der Valk P., de Vries H.E. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic. Biol. Med. 2008, 45:1729-1737.
53. van Horssen J., Witte M.E., Schreibelt G., de Vries H.E. Radical changes in multiple sclerosis pathogenesis. Biochim. Biophys. Acta 2011, 1812:141-150.
54. Shi P., Wei Y., Zhang J., Gal J., Zhu H. Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. J. Alzheimers Dis. 2010, 20(Suppl 2):S311-S324.
55. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
56. Higgins C.M., Jung C., Ding H., Xu Z. Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J. Neurosci. 2002, 22:RC215.
57. Pasinelli P., Belford M.E., Lennon N., Bacskai B.J., Hyman B.T., Trotti D., Brown R.H. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004, 43:19-30.
58. Dupuis L., de Tapia M., Rene F., Lutz-Bucher B., Gordon J.W., Mercken L., Pradier L., Loeffler J.P. Differential screening of mutated SOD1 transgenic mice reveals early up-regulation of a fast axonal transport component in spinal cord motor neurons. Neurobiol. Dis. 2000, 7:274-285.
59. Turchan-Cholewo J., Dimayuga F.O., Gupta S., Keller J.N., Knapp P.E., Hauser K.F., Bruce-Keller A.J. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J. Neurochem. 2009, 108:202-215.
60. Turchan-Cholewo J., Dimayuga V.M., Gupta S., Gorospe R.M., Keller J.N., Bruce-Keller A.J. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid. Redox Signal. 2009, 11:193-204.
61. Jung J.E., Kim G.S., Chen H., Maier C.M., Narasimhan P., Song Y.S., Niizuma K., Katsu M., Okami N., Yoshioka H., Sakata H., Goeders C.E., Chan P.H. Reperfusion and neurovascular dysfunction in stroke: from basic mechanisms to potential strategies for neuroprotection. Mol. Neurobiol. 2010, 41:172-179.
62. Davalos A., Castillo J., Marrugat J., Fernandez-Real J.M., Armengou A., Cacabelos P., Rama R. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 2000, 54:1568-1574.
63. Qian Z.M., Shen X. Brain iron transport and neurodegeneration. Trends Mol. Med. 2001, 7:103-108.
64. Chrissobolis S., Miller A.A., Drummond G.R., Kemp-Harper B.K., Sobey C.G. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front. Biosci. 2011, 16:1733-1745.
65. Gu Y., Zheng G., Xu M., Li Y., Chen X., Zhu W., Tong Y., Chung S.K., Liu K.J., Shen J. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury. J. Neurochem. 2012, 120:147-156.
66. Gu Y., Dee C.M., Shen J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability. Front. Biosci. (Schol. Ed.) 2011, 3:1216-1231.
67. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
68. Liebner S., Czupalla C.J., Wolburg H. Current concepts of blood-brain barrier development. Int. J. Dev. Biol. 2011, 55:467-476.
69. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37:13-25.
70. Agarwal R., Shukla G.S. Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem. Res. 1999, 24:1507-1514.
71. Vatassery G.T. Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics 1998, 53(Suppl 1):S25-S27.
72. Miao L., St Clair D.K. Regulation of superoxide dismutase genes: implications in disease. Free Radic. Biol. Med. 2009, 47:344-356.
73. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010, 459:923-939.
74. Tufekci K.U., Civi Bayin E., Genc S., Genc K. The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinsons Dis 2011, 2011:314082.
75. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13:76-86.
76. Merrill J.E., Murphy S.P. Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav. Immun. 1997, 11:245-263.
77. Dawson T.M., Snyder S.H. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J. Neurosci. 1994, 14:5147-5159.
78. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 1998, 19:33-36.
79. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:924-929.
80. Zarkovic K. 4-hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 2003, 24:293-303.
81. Mooradian A.D. Effect of aging on the blood-brain barrier. Neurobiol. Aging 1988, 9:31-39.
82. Allen C.L., Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int. J. Stroke 2009, 4:461-470.
83. Miller A.A., Dusting G.J., Roulston C.L., Sobey C.G. NADPH-oxidase activity is elevated in penumbral and non-ischemic cerebral arteries following stroke. Brain Res. 2006, 1111:111-116.
84. Paravicini T.M., Chrissobolis S., Drummond G.R., Sobey C.G. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 2004, 35:584-589.
85. Faraci F.M., Sobey C.G. Role of potassium channels in regulation of cerebral vascular tone. J. Cereb. Blood Flow Metab. 1998, 18:1047-1063.
86. Rascol O., Lozano A., Stern M., Poewe W. Milestones in Parkinson's disease therapeutics. Mov. Disord. 2011, 26:1072-1082.
87. Riederer P., Lachenmayer L., Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 2004, 11:2033-2043.
88. Yamada M., Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004, 25:215-221.
89. Takahata K., Shimazu S., Katsuki H., Yoneda F., Akaike A. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J. Neural Transm. 2006, 113:151-158.
90. Lew M.F. The evidence for disease modification in Parkinson's disease. Int. J. Neurosci. 2011, 121(Suppl 2):18-26.
91. Bertolini F., Novaroli L., Carrupt P.A., Reist M. Novel screening assay for antioxidant protection against peroxyl radical-induced loss of protein function. J. Pharm. Sci. 2007, 96:2931-2944.
92. Martinez-Martin P., O'Brien C.F. Extending levodopa action: COMT inhibition. Neurology 1998, 50:S27-S32. (discussion S44-28).
93. Merello M., Lees A.J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1994, 57:186-189.
94. Ferner R.E., Dear J.W., Bateman D.N. Management of paracetamol poisoning. BMJ 2011, 342:d2218.
95. Reichel C.M., Moussawi K., Do P.H., Kalivas P.W., See R.E. Chronic N-acetylcysteine during abstinence or extinction after cocaine self-administration produces enduring reductions in drug seeking. J. Pharmacol. Exp. Ther. 2011, 337:487-493.
96. Camfield D.A., Sarris J., Berk M. Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:887-895.
97. Kamboj S.S., Chopra K., Sandhir R. Hyperglycemia-induced alterations in synaptosomal membrane fluidity and activity of membrane bound enzymes: beneficial effect of N-acetylcysteine supplementation. Neuroscience 2009, 162:349-358.
98. Deigner H.P., Haberkorn U., Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin. Investig. Drugs 2000, 9:747-764.
99. Kerksick C., Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J Int Soc Sports Nutr 2005, 2:38-44.
100. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 1989, 6:593-597.
101. Hara R., Inomata Y., Kawaji T., Sagara N., Inatani M., Fukushima M., Tanihara H. Suppression of choroidal neovascularization by N-acetyl-cysteine in mice. Curr. Eye Res. 2010, 35:1012-1020.
102. Shi R., Huang C.C., Aronstam R.S., Ercal N., Martin A., Huang Y.W. N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacol. 2009, 9:7.
103. Sharma P., Sinha M., Shukla R., Garg R.K., Verma R., Singh M.K. A randomized controlled clinical trial to compare the safety and efficacy of edaravone in acute ischemic stroke. Ann Indian Acad Neurol 2011, 14:103-106.
104. Nakase T., Yoshioka S., Suzuki A. Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. BMC Neurol. 2011, 11:39.
105. Kawasaki T., Ishihara K., Ago Y., Baba A., Matsuda T. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J. Pharmacol. Exp. Ther. 2007, 322:274-281.
106. Isahaya K., Yamada K., Yamatoku M., Sakurai K., Takaishi S., Kato B., Hirayama T., Hasegawa Y. Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction. J. Stroke Cerebrovasc. Dis. 2012, 21:102-107.
107. Nakamura T., Kuroda Y., Yamashita S., Zhang X., Miyamoto O., Tamiya T., Nagao S., Xi G., Keep R.F., Itano T. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 2008, 39:463-469.
108. Yagi K., Kitazato K.T., Uno M., Tada Y., Kinouchi T., Shimada K., Nagahiro S. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009, 40:626-631.
109. Frei B. Efficacy of dietary antioxidants to prevent oxidative damage and inhibit chronic disease. J. Nutr. 2004, 134:3196S-3198S.
110. Edeas M. Strategies to target mitochondria and oxidative stress by antioxidants: key points and perspectives. Pharm. Res. 2011, 28:2771-2779.
111. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker?. Free Radic. Biol. Med. 2002, 32:968-974.
112. Farbstein D., Kozak-Blickstein A., Levy A.P. Antioxidant vitamins and their use in preventing cardiovascular disease. Molecules 2010, 15:8098-8110.
113. Leppala J.M., Virtamo J., Fogelholm R., Huttunen J.K., Albanes D., Taylor P.R., Heinonen O.P. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler. Thromb. Vasc. Biol. 2000, 20:230-235.
114. Grundman M., Delaney P. Antioxidant strategies for Alzheimer's disease. Proc. Nutr. Soc. 2002, 61:191-202.
115. Jeandel C., Nicolas M.B., Dubois F., Nabet-Belleville F., Penin F., Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989, 35:275-282.
116. Foy C.J., Passmore A.P., Vahidassr M.D., Young I.S., Lawson J.T. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM 1999, 92:39-45.
117. Bourdel-Marchasson I., Delmas-Beauvieux M.C., Peuchant E., Richard-Harston S., Decamps A., Reignier B., Emeriau J.P., Rainfray M. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing 2001, 30:235-241.
118. Riviere S., Birlouez-Aragon I., Nourhashemi F., Vellas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int. J. Geriatr. Psychiatry 1998, 13:749-754.
119. Zaman Z., Roche S., Fielden P., Frost P.G., Niriella D.C., Cayley A.C. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 1992, 21:91-94.
120. Sinclair A.J., Bayer A.J., Johnston J., Warner C., Maxwell S.R. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int. J. Geriatr. Psychiatry 1998, 13:840-845.
121. Engelhart M.J., Geerlings M.I., Ruitenberg A., Van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Diet and risk of dementia: does fat matter?: The Rotterdam Study. Neurology 2002, 59:1915-1921.
122. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002, 287:3223-3229.
123. Paleologos M., Cumming R.G., Lazarus R. Cohort study of vitamin C intake and cognitive impairment. Am. J. Epidemiol. 1998, 148:45-50.
124. Bin Q., Hu X., Cao Y., Gao F. The role of vitamin E (tocopherol) supplementation in the prevention of stroke. A meta-analysis of 13 randomised controlled trials. Thromb. Haemost. 2011, 105:579-585.
125. Boothby L.A., Doering P.L. Vitamin C and vitamin E for Alzheimer's disease. Ann. Pharmacother. 2005, 39:2073-2080.
126. Halliwell B. Establishing the significance and optimal intake of dietary antioxidants: the biomarker concept. Nutr. Rev. 1999, 57:104-113.
127. Basuroy S., Bhattacharya S., Leffler C.W., Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am. J. Physiol. Cell Physiol. 2009, 296:C422-C432.
128. Touyz R.M., Briones A.M., Sedeek M., Burger D., Montezano A.C. NOX isoforms and reactive oxygen species in vascular health. Mol. Interv. 2011, 11:27-35.
129. Bruce-Keller A.J., Gupta S., Knight A.G., Beckett T.L., McMullen J.M., Davis P.R., Murphy M.P., Van Eldik L.J., St Clair D., Keller J.N. Cognitive impairment in humanized APPxPS1 mice is linked to Abeta(1-42) and NOX activation. Neurobiol. Dis. 2011, 44:317-326.
130. Bruce-Keller A.J., Gupta S., Parrino T.E., Knight A.G., Ebenezer P.J., Weidner A.M., LeVine H., Keller J.N., Markesbery W.R. NOX activity is increased in mild cognitive impairment. Antioxid. Redox Signal. 2010, 12:1371-1382.
131. Bruce-Keller A.J., White C.L., Gupta S., Knight A.G., Pistell P.J., Ingram D.K., Morrison C.D., Keller J.N. NOX activity in brain aging: exacerbation by high fat diet. Free Radic. Biol. Med. 2010, 49:22-30.
132. Touyz R.M., Briones A.M. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens. Res. 2011, 34:5-14.
133. Carrano A., Hoozemans J.J., van der Vies S.M., Rozemuller A.J., van Horssen J., de Vries H.E. Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid. Redox Signal. 2011, 15:1167-1178.
134. Lassegue B., Griendling K.K. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 2010, 30:653-661.
135. Sorond F.A., Ratan R.R. Ironing-out mechanisms of neuronal injury under hypoxic-ischemic conditions and potential role of iron chelators as neuroprotective agents. Antioxid. Redox Signal. 2000, 2:421-436.
136. McCaffrey G., Willis C.L., Staatz W.D., Nametz N., Quigley C.A., Hom S., Lochhead J.J., Davis T.P. Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J. Neurochem. 2009, 110:58-71.